Kelly John Alexander 4

4 · PRECISION BIOSCIENCES INC · Filed Feb 19, 2026

AI-generated summary of this filing

Updated Feb 19, 2026

Precision BioSciences (DTIL) CFO Kelly Alexander Receives RSUs, Sells Shares

What Happened

Kelly John Alexander, Chief Financial Officer of Precision BioSciences (DTIL), had 27,584 Restricted Stock Units (RSUs) vest on Feb 17, 2026 (treated as an acquisition at $0.00) and sold 8,149 of the resulting shares on Feb 18, 2026 at $3.84 each for proceeds of $31,292. The sale was a sell-to-cover to satisfy tax withholding obligations tied to the RSU settlement.

Key Details

Transaction dates and prices:
- Feb 17, 2026: 27,584 RSUs vested => 27,584 shares acquired at $0.00 (award settlement).
- Feb 18, 2026: 8,149 shares sold open market/private sale at $3.84 each for $31,292.
Net effect: 27,584 shares vested and 8,149 sold to cover taxes → net increase of 19,435 shares retained from this vesting event.
Footnotes: Sales were effected under a Rule 10b5-1 plan adopted Jan 17, 2025 and were explicitly sell-to-cover for tax withholding. Each RSU equals one share; RSUs vest in three substantially equal annual installments beginning Feb 17, 2026.
Filing: Form 4 filed Feb 19, 2026 (appears to be filed within the standard two-business-day window).

Context

This was not a discretionary sell for liquidity or investment judgment — the sale was to meet tax-withholding tied to RSU vesting under a pre-established 10b5-1 plan. For retail investors, routine sell-to-cover transactions are common following awards and do not necessarily signal management’s view of the stock.

Form 4

Period: 2026-02-17

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-02-17+27,584→ 134,032 total
Sale
Common Stock
[F3]
2026-02-18$3.84/sh−8,149$31,292→ 125,883 total
Exercise/Conversion
Restricted Stock Units
[F2][F4]
2026-02-17−27,584→ 55,166 total
→ Common Stock (27,584 underlying)

Footnotes (4)

[F1]Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026.
[F2]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
[F3]The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
[F4]RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Signature

/s/ Dario Scimeca, Attorney-in-fact for John Alexander Kelly|2026-02-19

1 file